Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T08:47:03.988Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-0626 – Long-term Safety of Methylphenidate Hydrochloride Modified Release (MPH-LA) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Published online by Cambridge University Press:  15 April 2020

Y. Ginsberg ,
T. Tvedten ,
T. Arngrim ,
A. Philipsen ,
P. Gandhi ,
CW. Chen ,
V. Kumar  and
M. Huss
Y. Ginsberg
Affiliation:
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
T. Tvedten
Affiliation:
Centre for Therapy and Supervision, Centre for Therapy and Supervision, Skien, Norway
T. Arngrim
Affiliation:
Private Clinic, Private Clinic, Aarhus, Denmark
A. Philipsen
Affiliation:
University Medical Centre, University Medical Centre, Freiburg, Germany
P. Gandhi
Affiliation:
Novartis Healthcare Pvt. Ltd., Novartis Healthcare Pvt. Ltd., Madhapur Hyderabad, India
CW. Chen
Affiliation:
Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, East Hanover, USA
V. Kumar
Affiliation:
Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, East Hanover, USA
M. Huss
Affiliation:
Department of Child and Adolescent Psychiatry, University of Medicine, Mainz, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

A previous 40-week, randomised, double-blind placebo-controlled core study [comprising of dose confirmation (9-week), real-life dose optimisation (5-week) and maintenance of effect phases (6-month)] reported the safety of MPH-LA in the treatment of adult ADHD. Here, we report the long-term safety from the extension phase (6-month) of this core study.

Methods:

During the extension phase, patients initiated treatment with MPH-LA 20 mg/day; up-titrated to an optimal dose of 40, 60 or 80 mg/day in increments of 20 mg/week. Safety was analysed from baseline of maintenance of effect phase (core study); and from baseline of extension phase to end of extension phase. Adverse events (AEs) and serious adverse events (SAEs) were reported.

Results:

Incidence of AEs occurring anytime starting from baseline of the maintenance of effect phase (core study) until the end of extension phase was 80.5%. The incidence of AEs occurring in the extension phase period was 69.8% (Table). Incidence of serious AEs (SAEs) reported during both periods were similar (0.7%). Most common AEs were nasopharyngitis, headache, decreased appetite, dry mouth and nausea. No deaths were reported. No new or unexpected results were observed for laboratory findings, vital signs or ECGs. None of the patients had QT, QTcB or QTcF ≥500ms during the study.

Conclusions:

Long-term treatment with MPH-LA in adult ADHD patients was well-tolerated.

Table: Number (%) of patients with most frequent AEs and SAEs

 AEs occuring anytime starting from the baseline of maintenance of effect phase (core study) to the end of extension phaseAEs occuring anytime in the extension phase
(Preferred Term ≥5%)
 N=298 n (%)N=298 n (%)
Total AEs240(80.5)208(69.8)
Nasopharyngitis79(26.5)57(19.1)
Headache62(20.8)42(14.1)
Decreased appetite26(8.7)23 (7.7)
Dry mouth24(8.1)20 (6.7)
Nausea18(6.0)15 (5.0)
Upper respiratory tract infection17(5.7)14(4.7)
Diarrhoea15(5.0)6 (2.0)
Total SAEs2(0.7)2(0.7)
Pancreatitis1 (0.3)1 (0.3)
Exostosis1 (0.3)1 (0.3)
Non-Hodgkin's lyrnphorna1 (0.3)1 (0.3)

Type
EPW09 - Psychopharmacology and Pharmacoeconomics 1
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.